Goldman, Sachs

Goldman Sachs Shares Surge to New Peak on M&A Optimism

10.12.2025 - 21:42:04

Marcus US5663301068

Shares of Goldman Sachs Group Inc. reached a fresh 52-week high this week, propelled by a bullish internal forecast for mergers and acquisitions and the unveiling of new strategic plans. The stock price climbed to $893.56 on Wednesday before closing the session at $892.13, marking a gain of 1.77%.

The equity's advance followed a presentation by Chief Financial Officer Denis Coleman, who projected that 2026 could become the second-strongest year on record for global M&A activity. He pointed to a notable increase in deal-making already underway, citing 63 "mega-deals" valued above $10 billion each that had been announced by the end of November 2025.

This optimistic outlook from the bank's own finance chief appears to be reinforcing positive sentiment among market participants. Analysts have recently echoed this confidence; Bank of America, for instance, raised its price target for Goldman Sachs to $900, highlighting the firm's advantageous positioning within a recovering capital markets landscape.

Strategic Moves to Fuel Growth

Concurrent with this forecast, the firm is pushing forward with strategic initiatives designed to bolster efficiency and expansion. Internally, Goldman Sachs introduced "OneGS 3.0," a company-wide program focused on leveraging artificial intelligence to enhance productivity across its operations. Despite previous efficiency measures, the bank anticipates a net increase in its headcount for 2025 to support this expected growth phase.

Should investors sell immediately? Or is it worth buying Marcus?

Externally, its asset management arm is broadening its European footprint. Goldman Sachs Asset Management (GSAM) recently launched three new actively managed bond ETFs, which are now listed on the Deutsche Börse. This expansion brings its total offering to eight such products, aiming to meet rising investor demand for transparent, active fixed-income strategies.

Technical Momentum and Upcoming Catalyst

From a technical perspective, the breakout to new highs confirms the upward momentum previously identified by market experts. Analysts suggest the bullish trend remains intact as long as the share price holds above the prior resistance level of $885.

Investor attention is now firmly set on January 15, 2026, the anticipated date for Goldman Sachs's release of its annual and quarterly financial results. The market will be scrutinizing whether the predicted surge in M&A activity translates immediately into advisory fee revenue, or if the significant revenue impact will materialize later in the second half of 2026. The coming earnings report will serve as a critical test for the CFO's promising forecast.

Ad

Marcus Stock: Buy or Sell?! New Marcus Analysis from December 10 delivers the answer:

The latest Marcus figures speak for themselves: Urgent action needed for Marcus investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 10.

Marcus: Buy or sell? Read more here...

@ boerse-global.de | US5663301068 GOLDMAN

Weitere Meldungen

ANALYSE-FLASH: Goldman dreht Givaudan von 'Buy' auf 'Sell' - Setzen auf Symrise Die US-Investmentbank Goldman Sachs hat das Kursziel für Givaudan CH0010645932 von 4100 auf 2900 Franken gesenkt und die Schätzung der Aktien von "Buy" auf "Sell" gedreht. (Boerse, 10.02.2026 - 10:34) weiterlesen...

ANALYSE-FLASH: Goldman hebt Lanxess auf 'Neutral' - Ziel hoch auf 23 Euro Die US-Investmentbank Goldman Sachs hat das Kursziel für Lanxess DE0005470405 von 10 auf 23 Euro angehoben und die Aktien von "Sell" auf "Neutral" hochgestuft. (Boerse, 10.02.2026 - 10:20) weiterlesen...

ANALYSE-FLASH: Goldman hebt Symrise auf 'Buy' - Ziel hoch auf 83 Euro Die US-Investmentbank Goldman Sachs hat das Kursziel für Symrise DE000SYM9999 von 70 auf 83 Euro angehoben und die Aktien von "Neutral" auf "Buy" hochgestuft. (Boerse, 10.02.2026 - 10:20) weiterlesen...

ANALYSE-FLASH: Goldman dreht Evonik von 'Sell' auf 'Buy' - Ziel 18 Euro Die US-Investmentbank Goldman Sachs hat das Kursziel für Evonik DE000EVNK013 von 11,60 auf 18 Euro angehoben und die Einstufung der Aktien von "Sell" auf "Buy" gedreht. (Boerse, 10.02.2026 - 10:05) weiterlesen...

AKTIEN IM FOKUS: Goldman optimistischer für Chemie - Evonik und Symrise stark Eine insgesamt optimistischere Einschätzung der europäischen Chemiebranche EU0009658608 durch Goldman Sachs bewegt am Dienstagmorgen insbesondere die Kurse von Evonik DE000EVNK013 und Symrise DE000SYM9999. (Boerse, 10.02.2026 - 08:28) weiterlesen...

ANALYSE-FLASH: Goldman belässt Bayer auf 'Buy' - Ziel 54,50 Euro Die US-Investmentbank Goldman Sachs hat die Einstufung für Bayer DE000BAY0017 nach Asundexian-Studiendaten mit einem Kursziel von 54,50 Euro auf "Buy" belassen. (Boerse, 06.02.2026 - 10:05) weiterlesen...